Junshi Biosciences (HKG:1877, SHA:688180) dosed the first patient in a phase III trial of JS203, its bispecific antibody candidate for relapsed or refractory diffuse large B-cell lymphoma.

The trial will compare JS203 combined with chemotherapy against rituximab plus chemotherapy in 282 patients, according to a Friday Hong Kong bourse filing. Overall survival is the primary endpoint.

Shares of the biopharmaceutical company fell 1% by midday Monday.